quarterly out

AVITA MEDICAL MARCH 2012 QUARTERLY CASHFLOW
Highlights

? March Quarterly Revenues $1.0m

? 23% increase in FY12 YTD Q3 Revenues compared to FY11 YTD Q3

? 104% increase in ReCell Revenues FY12 Q3 compared to

FY11 Q3

? Cash Reserves $9.4m

Summary of Quarter ending 31 March 2012

? Total revenues for the Quarter (including royalties and interest) were $1 million, an 11% increase over the corresponding March 2011 Quarter. Cash receipts for the Quarter were
$961k. March Quarter revenues are historically the lowest of the year due to reduced
demand for respiratory products during the Australian summer and relatively fewer
aesthetic and other elective procedures during January in Europe.
? Total revenues for the Year-to-Date 31 March 2012 were $3.7 million, a 23% increase over
the corresponding YTD March 2011 Quarter.
? ReCell revenues continue to drive company growth, increasing 104% over the
corresponding 2011 period. This increase reflects the continued increase in usage and
growing acceptance of ReCell in the core European markets among key ReCell users and
clinical centres.
? Revenues from the Company’s respiratory product line (Breath-A-Tech and Funhaler) were
down approximately 13% compared to the previous March 2011 Quarter; this decrease is
in large part due to the Company’s decision to cease sales and marketing efforts for the
respiratory line outside of Australia.
? Overall Gross Margins remain above 73% for the Quarter.
? Losses due to Operating cash flows for the Quarter were $1.4M, compared to losses of
$1.2M during the corresponding March 2011 Quarter. Losses reflect the increased
expenditure on Sales & Marketing efforts (up 66%) and Research and Clinical Studies (up
69%).
? Cash-at-bank at end of Quarter: $9.4 million.